The last week was a fabulous one for the bulls as the key benchmark indices closed in positive terrain on all trading sessions of the week. The bulls like to carry the positive baton from last trading week and the Indian markets are set to start the week on a positive note on the back of a strong close on Wall Street in Friday’s trade and also, cheerful cues from Asian peers are helping the cause.

The stocks to watch out on November 4 include Kansai Nerolac, NCC, Tata Power, IndiGo, and Tata Motors.

The following stocks will be in focus during Monday’s trading session in light of their results announcements: Escorts, Unichem Laboratories, Advanced Enzyme Technologies, Relaxo Footwears and BEML.

Along with robust volumes, the stock of Ipca Laboratories Limited has given a downward sloping trendline breakout on the daily time frame. Additionally, the stock had formed an opening bullish Marubozu candle on the breakout day, which added strength to the breakout.

Our Bollinger Band Squeeze scanner picked PVR limited, which indicates that the stock is near a consolidation breakout.

The stock of Mishra Dhatu Nigam Limited has given a symmetrical triangle breakout on the weekly time frame. This breakout was confirmed by the above 50-week average volumes.

Considering the daily time frame, the stock of Bajaj Finserv Limited has given a breakout of bullish flag pattern, suggesting an upside move in the counter. This breakout was confirmed by the above 50-day average volume.

The stock of ICICI Bank Limited has formed a shooting Star candlestick pattern on the weekly time frame. The shooting Star candlestick formation is viewed as a bearish reversal candlestick pattern, which typically occurs at the top of an uptrend.

Promoters of Jyothy Labs sold 4 per cent of the company's shares worth Rs. 260 crore in a block deal. Promoters had invested in the company during Henkel's acquisition.

Cadila Healthcare’s manufacturing facility located in Baddi, has received the Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA), stating that the classification of the facility is in ‘No Action Indicated (NAI)'. The USFDA had conducted inspection at the company’s formulations manufacturing facility at Baddi in Himachal Pradesh from July 15-19, 2019.